1. Clinical Trial Data (SURMOUNT Series)

• SURMOUNT-1 (2022): 15-20% body weight loss at 72 weeks
• SURMOUNT-2 (2023): 16.3% weight loss in obese diabetics
• 2024 updates: 22.5% weight loss in high-dose groups

2. Real User Case Studies

• 3 anonymized patient journeys (with progress charts)
• Average results:
  • Month 1: 4-6% weight loss
  • Month 3: 10-12% reduction
  • Month 6: 15%+ sustained loss

3. Comparative Analysis

• Tirzepatide vs. Semaglutide (SURPASS-6 trial data):
  • 2.1% greater weight reduction
  • Fewer GI side effects

4. Usage Guidelines

• Titration schedule (2.5mg ? 5mg ? 10mg ? 15mg)
• Injection site rotation diagram
• Lifestyle integration tips

Compliance Note:
“Tirzepatide is FDA-approved as Zepbound™ for chronic weight management in adults with BMI ?30 or ?27 with comorbidities. Consult a physician before use.”